107
Views
8
CrossRef citations to date
0
Altmetric
Original

CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: A retrospective study

, , , , , , & show all
Pages 506-512 | Received 02 Aug 2006, Accepted 30 Oct 2006, Published online: 01 Jul 2009

References

  • Benson C A, Kaplan J E, Masur H, Pau A, Holmes K K. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis 2005; 40: S131
  • Cheson B D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431–2448
  • Laurenti L, Piccioni P, Piccirillo N, Sora F, Chiusolo P, Garzia M, et al. Immune recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in group of 149 patients. Leuk Lymphoma 2004; 45: 2063–2070
  • Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
  • Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
  • Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single vs. double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
  • Goldschmidt H, Sonneveld P, Cremer F W, van der Holt B, Westveer P, Breitkreutz I, et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 2003; 82: 654–659
  • Dykewicz C A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139–144
  • Harousseau J L. Stem cell transplantation in multiple myeloma (0, 1, or 2). Curr Opin Oncol 2005; 17: 93–98
  • Douek D C, Vescio R A, Betts M R, Brenchley J M, Hill B J, Zhang L, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000; 355: 1875–1881
  • Rosinski S L, McNiece I K, Shpall E J, Clough N, Russell P, Blunk B, et al. Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone Marrow Transplant 2005; 27: 27
  • Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C, et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999; 106: 191–197

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.